Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,745
  • Shares Outstanding, K 7,689
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,580 K
  • 60-Month Beta -0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.55
Trade KPRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.68
  • Most Recent Earnings $-0.89 on 11/09/23
  • Latest Earnings Date 05/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +100,000.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5339 +25.55%
on 03/19/24
0.7001 -4.26%
on 03/06/24
-0.0097 (-1.43%)
since 02/28/24
3-Month
0.5013 +33.71%
on 01/11/24
0.9980 -32.84%
on 02/01/24
+0.1156 (+20.84%)
since 12/28/23
52-Week
0.4622 +45.02%
on 09/05/23
5.2500 -87.23%
on 04/27/23
-2.8697 (-81.06%)
since 03/28/23

Most Recent Stories

More News
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the...

KPRX : 0.6800 (+10.19%)
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

Kiora to webcast investor conference call at 5:30 pm today; details belowEncinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ:...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing...

KPRX : 0.6800 (+10.19%)
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional visionFunctional MRI demonstrates...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - October 3, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional patients...

KPRX : 0.6800 (+10.19%)
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Encinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as...

KPRX : 0.6800 (+10.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kiora Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company. It involved in developing and commercializing products for treating ophthalmic diseases. The company's product pipeline includes KIO-301, KIO-101 and KIO-201. Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 0.6464
2nd Resistance Point 0.6337
1st Resistance Point 0.6254
Last Price 0.6800
1st Support Level 0.6044
2nd Support Level 0.5917
3rd Support Level 0.5834

See More

52-Week High 5.2500
Fibonacci 61.8% 3.4211
Fibonacci 50% 2.8561
Fibonacci 38.2% 2.2911
Last Price 0.6800
52-Week Low 0.4622

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar